GLP-1 agonists (GLP-1s), including semaglutide, liraglutide, dulaglutide, and tirzepatide, are exogenous incretin mimetics that can bind to GLP-1R independently of food intake, effectively managing diabetes and promoting weight loss in obesity. Here, GCG is linked to obesity disorder.